文献速递脊柱关节炎其他结缔组织病

合并症对银屑病关节炎患者TNF抑制剂治疗的影响:一项人群队列研究

Impact of Comorbidities on Tumor Necrosis Factor Inhibitor Therapy in Psoriatic Arthritis: A Population-Based Cohort Study.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2018-03-07

该研究基于丹麦DANBIO注册和国民患者登记,纳入1750例首次使用TNFi的银屑病关节炎患者。结果显示,CCI≥2分或合并抑郁/焦虑者TNFi持续用药时间更短,且CCI≥2分者6个月EULAR良好应答比例更低。

要点

  • CCI≥2分与TNFi持续用药时间缩短相关(HR 1.72,95%CI 1.26-2.37;P=0.001)。
  • 合并抑郁和/或焦虑者TNFi持续用药时间也显著缩短(log-rank P=0.027)。
  • CCI≥2分者6个月EULAR良好应答及良好或中等应答比例均更低(P<0.001)。

核心结论

  • 合并症与银屑病关节炎患者更高的基线疾病活动度、更短的TNFi持续用药时间和更低的临床应答率相关。

研究设计与样本

  • 基于丹麦DANBIO注册和丹麦国民患者登记的人群队列研究,纳入1750例首次使用TNFi的银屑病关节炎患者,采用Kaplan-Meier法和Cox比例风险回归分析。

主要发现

  • CCI评分越高者基线疾病活动度指标越高,抑郁和/或焦虑发生率也越高。
  • CCI≥2分者TNFi持续用药时间较无合并症者缩短(log-rank P<0.001)。
  • 合并抑郁和/或焦虑者TNFi持续用药时间较无合并症者缩短(log-rank P=0.027)。
  • 多因素分析中CCI≥2分与TNFi持续用药时间缩短相关(HR 1.72,95%CI 1.26-2.37;P=0.001)。
  • CCI≥2分者6个月达到EULAR良好应答及良好或中等应答的比例均低于无合并症者(P<0.001)。

关键数值与推荐

  • 合并症依据Charlson合并症指数(CCI)评估,通过链接丹麦国民患者登记获取。
  • TNFi持续用药时间缩短的阈值定义为CCI评分≥2分(对比无合并症者)。
  • 临床应答采用EULAR良好应答及良好或中等应答标准,评估时间点为6个月。

临床怎么用

  • 对首次使用TNFi的银屑病关节炎患者应评估合并症负担(CCI评分)及抑郁/焦虑状态。
  • 合并症负担较高(CCI≥2分)或合并抑郁/焦虑者需预期TNFi持续用药时间可能更短、应答率可能更低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this population-based cohort study was to investigate the impact of comorbidities on disease activity, treatment response, and persistence with the first-tried tumor necrosis factor inhibitor (TNFi) in patients with psoriatic arthritis (PsA). METHODS: Data on patient characteristics, disease activity, and treatment response and persistence were obtained from the DANBIO registry. Information on comorbidities according to the Charlson Comorbidity Index (CCI) was obtained through linkage with the Danish National Patient Register. Kaplan-Meier plots and Cox proportional hazard regression analyses were performed. Percentages of patients achieving relevant clinical responses were calculated. RESULTS: We identified 1,750 patients eligible for analyses. Patients with higher CCI scores had higher disease activity measures at baseline and increased occurrence of depression and/or anxiety. Kaplan-Meier curves showed shorter persistence with treatment for patients with a CCI score ≥2 (log-rank P < 0.001) and for patients with depression and/or anxiety (P = 0.027) compared to patients without comorbidities. In multivariate analysis, a CCI score ≥2 was associated with reduced TNFi persistence compared with patients without comorbidities (hazard ratio 1.72 [95% confidence interval 1.26-2.37]; P = 0.001). A smaller proportion of patients with a CCI score ≥2 achieved European League Against Rheumatism (EULAR) good response (P < 0.001) and EULAR good-or-moderate response (P < 0.001) at 6 months compared with patients without comorbidities. CONCLUSION: The presence of comorbidities was associated with higher baseline disease activity, shorter TNFi persistence, and reduced clinical response rates in a cohort of Danish patients with PsA.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Ballegaard C, Højgaard P, Dreyer L, et al. Impact of Comorbidities on Tumor Necrosis Factor Inhibitor Therapy in Psoriatic Arthritis: A Population-Based Cohort Study. Arthritis Care Res (Hoboken). 2018. PMID: 28772007. doi:10.1002/acr.23333

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。